Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

In adults with psoriasis, adding methotrexate to adalimumab did not improve effectiveness or drug survival compared with ...

Central adiposity measures are strongly associated with psoriasis risk, with a stronger association in women, according to a ...

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

Both mild and moderate-to-severe psoriasis are significantly associated with an increased risk for sleep disorders, according ...

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

“I found ways to cover it on stage, in photos and in my day-to-day life ... the Food and Drug Administration in 2018 for the treatment of moderate-to-severe plaque psoriasis. Garfunkel is the most ...

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety ... Copies of these filings are available online at www.sec.gov, www.jnj.com ...

84% of adolescents with moderate-to-severe plaque ... online April 25, 2020]. J Am Acad Dermatol. doi: 10.1016/j.jaad.2020.04.104. Accessed April 2025. 3 Thompson Jr, D. How the Psoriasis Area ...

A once-daily TYK2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque psoriasis, according to a presenter. Image: Adobe Stock. The primary endpoint was the ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD Topline ...